Amended Statement of Ownership (sc 13g/a)
February 08 2021 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 4)
ZYNERBA
PHARMACEUTICALS, INC.
(Name of
Issuer)
Common
Stock, $0.001 par value
(Title of
Class of Securities)
98986X109
(CUSIP Number)
December
31, 2020
(Date of
Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
*The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information required in the
remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP No: 98986X109
|
(1)
|
Names of Reporting Persons
|
|
|
Michael Rapoport
|
|
|
|
|
(2)
|
Check the Appropriate Box if a Member of a Group (See Instructions)
|
|
|
|
|
|
(a)
|
¨
|
|
|
|
|
|
|
(b)
|
¨
|
|
|
|
|
(3)
|
SEC Use Only
|
|
|
|
|
(4)
|
Citizenship or Place of Organization
|
|
|
United States of America
|
|
|
|
|
|
Number of Shares Beneficially Owned by Each Reporting
Person With
|
|
|
|
|
|
(5)
|
Sole Voting Power
|
|
|
|
0
|
|
|
|
|
|
|
(6)
|
Shared Voting Power
|
|
|
|
0
|
|
|
|
|
|
|
(7)
|
Sole Dispositive Power
|
|
|
|
0
|
|
|
|
|
|
|
(8)
|
Shared Dispositive Power
|
|
|
|
0
|
|
|
|
|
|
(9)
|
Aggregate Amount Beneficially Owned by Each Reporting
Person
|
|
|
0 shares of Common Stock
|
|
|
|
|
(10)
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
|
|
|
|
(11)
|
Percent of Class Represented by Amount in Row (9)
|
|
|
0%
|
|
|
|
|
(12)
|
Type of Reporting Person (See Instructions)
|
|
|
IN
|
SCHEDULE
13G
CUSIP
No: 98986X109
Item 1.
|
(a)
|
Name
of Issuer
Zynerba Pharmaceuticals, Inc. (the “Issuer”)
|
|
(b)
|
Address
of Issuer’s Principal Executive Offices
80 W. Lancaster Avenue, Suite 300, Devon, PA 19333
|
Item 2 (a).
|
Name
of Person Filing
|
|
|
|
Michael
Rapoport
|
Item 2 (b).
|
Address
of Principal Business Office or, if none, Residence
|
|
|
|
105
S. Narcissus Avenue, Suite 705, West Palm Beach, FL 33401
|
Item 2 (c).
|
Citizenship
|
|
|
|
This Schedule 13G is being filed
on behalf of Michael Rapoport, an individual who is a citizen of the United States of America.
|
|
|
|
The principal business office
of Michael Rapoport is 105 S. Narcissus Avenue, Suite 705, West Palm Beach, FL 33401.
|
|
|
Item 2 (d)
|
Title of Class of Securities
|
|
Common Stock, par value $0.001
per share
|
|
|
Item 2 (e)
|
CUSIP Number
|
|
98986X109
|
Item 3.
|
If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c),
check whether the person filing is a:
|
Not
applicable.
Provide
the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
|
(a)
|
Amount Beneficially Owned:
|
Michael Rapoport –
0 shares of Common Stock
Michael Rapoport –
0%
|
(c)
|
Number of shares as to
which such person has:
|
|
(i)
|
sole power to vote or to
direct the vote
|
Michael Rapoport –
0 shares of Common Stock
|
(ii)
|
shared power to vote or
to direct the vote
|
Michael Rapoport –
0 shares
|
(iii)
|
sole power to dispose or
to direct the disposition of
|
Michael Rapoport –
0 shares of Common Stock
|
(iv)
|
shared power to dispose
or to direct the disposition of
|
Michael Rapoport –
0 shares
** The beneficial ownership
percentages herein are based on 29,439,175 shares of Common Stock issued and outstanding as of November 5, 2020, as disclosed
in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9,
2020.
Item 5.
|
Ownership
of Five Percent or Less of a Class
|
If this statement is being filed
to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent
of the class of securities, check the following: x
Item 6.
|
Ownership
of More than Five Percent on Behalf of Another Person
|
Not applicable.
Item 7.
|
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By
the Parent Holding Company or Control Person
|
Not applicable.
Item 8.
|
Identification
and Classification of Members of the Group
|
Not applicable.
Item 9.
|
Notice
of Dissolution of Group
|
Not applicable.
By signing below each
of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities
and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Date: February 5, 2021
|
/s/ Michael Rapoport
|
|
Michael Rapoport
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024